Month: September 2023

WINNEMUCCA, Nev., Sept. 27, 2023 (GLOBE NEWSWIRE) — Paramount Gold Nevada Corp. (NYSE American: PZG) (“Paramount” or the “Company”) is pleased to announce that its Annual General Meeting (“AGM” or the “meeting”) of the stockholders will be held on December 12, 2023 at 11:00 AM eastern standard time. The meeting will be held virtually over the Internet. Proxy materials will be available on or about October 30th, the mail date, at www.edocumentview.com/PZG and on the Company’s website. The Board of Directors has fixed the close of business on Monday, October 16, 2023 as the record date for the determination of the stockholders entitled to notice of, and to vote at, the AGM. The Company also advised that it filed its annual audited financial statements for the fiscal year ended June 30, 2023 on Form 10-K with the Securities and Exchange...

ELI-002 2P is an investigational therapeutic cancer vaccine targeting solid tumors driven by G12D and G12R mutations in KRAS As of the April 25, 2023 data cut-off date, among the 22 evaluable patients, preliminary data from the trial suggest that those with greater than median T cell response had not reached median Relapse-Free Survival compared to median RFS of 3.91 months for patients with less than median T cell response Updated data demonstrated 86% reduction in risk of progression or death in patients with large T cell responses induced by ELI-002 2P in the phase 1 study Elicio plans to initiate a randomized phase 2 study early in 2024 for ELI-002 7PBOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline...

VANCOUVER, British Columbia, Sept. 27, 2023 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce expected admission of its common shares to begin trading on the Access Segment of the AQSE Growth Market in the UK is expected to take place on October 10th, 2023. The AQSE Growth Market is a multilateral trading facility operated by Aquis Stock Exchange. A copy of the application announcement can be accessed at the following link: https://aqx-web-prod-s3-public-read.s3.eu-west-2.amazonaws.com/20230926_Application_Announcement_1_5533c9b702.pdf Management Commentary: Josh...

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) — Modulex Modular Buildings Plc (“Modulex”), a UK-based, globally focused “ConstrucTech” manufacturer of modular buildings today announced that it has filed a registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) on September 27, 2023 relating to its previously announced proposed business combination (the “Business Combination”) with PHP Ventures Acquisition Corp. (NASDAQ: PPHP) a publicly traded special purpose acquisition company (“PHP”). The Registration Statement contains a preliminary proxy statement/prospectus in connection with the Business Combination. Modulex is a cutting-edge, UK-headquartered “ConstrucTech” company offering Carbon Net Zero certified, advanced 3D volumetric steel modular buildings embedded with...

WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, California from November 1-5, 2023. The company plans to present preliminary anti-tumor activity, safety, pharmacokinetic and pharmacodynamic data from its Phase 1/2 clinical trial for XTX202, a tumor-activated, engineered, beta-gamma biased IL-2, as well as preclinical data for XTX301, a tumor-activated, engineered IL-12. Poster presentation details:Title: Phase 1/2 First-in-Human Study of XTX202, a Masked, Tumor-Activated IL-2βγ, in Patients with Advanced Solid...